The effects of omega-3 fatty acids monotherapy in Alzheimer's disease and mild cognitive impairment: A preliminary randomized double-blind placebo-controlled study

Aid, 2005, Dietary docosahexaenoic acid [22: 6(n−3)] as a phospholipid or a triglyceride enhances the potassium chloride-evoked release of acetylcholine in rat hippocampus, J Nutr, 135, 1008, 10.1093/jn/135.5.1008

1994

Boston, 2004, Ethyl-EPA in Alzheimer's disease—a pilot study, Prostaglandins Leukot Essent Fat Acids, 71, 341, 10.1016/j.plefa.2004.07.001

Cherrier, 2005, Testosterone improves spatial memory in men with Alzheimer disease and mild cognitive impairment, Neurology, 64, 2063, 10.1212/01.WNL.0000165995.98986.F1

Chiu, 2003, Polyunsaturated fatty acid deficit in patients with bipolar mania, Eur Neuropsychopharmacol, 13, 99, 10.1016/S0924-977X(02)00130-X

Conquer, 2000, Fatty acid analysis of blood plasma of patients with Alzheimer's disease, other types of dementia, and cognitive impairment, Lipids, 35, 1305, 10.1007/s11745-000-0646-3

Dullemeijer, 2007, n 3 fatty acid proportions in plasma and cognitive performance in older adults, Am J Clin Nutr, 86, 1479, 10.1093/ajcn/86.5.1479

Everitt, 1998, Analysis of longitudinal data. Beyond MANOVA, Br J Psychiatry, 172, 7, 10.1192/bjp.172.1.7

Fenton, 2000, Essential fatty acids, lipid membrane abnormalities, and the diagnosis and treatment of schizophrenia, Biol Psychiatry, 47, 8, 10.1016/S0006-3223(99)00092-X

Freund-Levi, 2008, Omega-3 supplementation in mild to moderate Alzheimer's disease: effects on neuropsychiatric symptoms, Int J Geriatr Psychiatry, 23, 161, 10.1002/gps.1857

Freund-Levi, 2006, Omega-3 fatty acid treatment in 174 patients with mild to moderate Alzheimer disease: OmegAD study: a randomized double-blind trial, Arch Neurol, 63, 1402, 10.1001/archneur.63.10.1402

Hachinski, 1975, Cerebral blood flow in dementia, Arch Neurol, 32, 632, 10.1001/archneur.1975.00490510088009

Hamilton, 1960, A rating scale for depression, J Neurol Neurosurg Psychiatry, 23, 56, 10.1136/jnnp.23.1.56

Hashimoto, 2005, Docosahexaenoic acid-induced amelioration on impairment of memory learning in amyloid beta-infused rats relates to the decreases of amyloid beta and cholesterol levels in detergent-insoluble membrane fractions, Biochim Biophys Acta, 1738, 91, 10.1016/j.bbalip.2005.11.011

Hashimoto, 2005, Chronic administration of docosahexaenoic acid ameliorates the impairment of spatial cognition learning ability in amyloid beta-infused rats, J Nutr, 135, 549, 10.1093/jn/135.3.549

Hibbeln, 1998, Fish consumption and major depression, Lancet, 351, 1213, 10.1016/S0140-6736(05)79168-6

Huang, 2005, Benefits of fatty fish on dementia risk are stronger for those without APOE epsilon4, Neurology, 65, 1409, 10.1212/01.wnl.0000183148.34197.2e

Issa, 2006, The efficacy of omega-3 fatty acids on cognitive function in aging and dementia: a systematic review, Dement Geriatr Cogn Disord, 21, 88, 10.1159/000090224

Jelic, 2006, Clinical trials in mild cognitive impairment: lessons for the future, J Neurol Neurosurg Psychiatry, 77, 429, 10.1136/jnnp.2005.072926

Kotani, 2006, Dietary supplementation of arachidonic and docosahexaenoic acids improves cognitive dysfunction, Neurosci Res, 56, 159, 10.1016/j.neures.2006.06.010

Lukiw, 2005, A role for docosahexaenoic acid-derived neuroprotectin D1 in neural cell survival and Alzheimer disease, J Clin Invest, 115, 2774, 10.1172/JCI25420

Marangell, 2003, A double-blind, placebo-controlled study of the omega-3 fatty acid docosahexaenoic acid in the treatment of major depression, Am J Psychiatry, 160, 996, 10.1176/appi.ajp.160.5.996

Mazza, 2007, Omega-3 fatty acids and antioxidants in neurological and psychiatric diseases: an overview, Prog Neuropsychopharmacol Biol Psychiatry, 31, 12, 10.1016/j.pnpbp.2006.07.010

Morris, 2003, Consumption of fish and n−3 fatty acids and risk of incident Alzheimer disease, Arch Neurol, 60, 940, 10.1001/archneur.60.7.940

Otsuka, 2000, [Analysis of dietary factors in Alzheimer's disease: clinical use of nutritional intervention for prevention and treatment of dementia], Nippon Ronen Igakkai Zasshi, 37, 970, 10.3143/geriatrics.37.970

Peet, 2001, Two double-blind placebo-controlled pilot studies of eicosapentaenoic acid in the treatment of schizophrenia, Schizophr Res, 49, 243, 10.1016/S0920-9964(00)00083-9

Peet, 2002, A dose-ranging study of the effects of ethyl-eicosapentaenoate in patients with ongoing depression despite apparently adequate treatment with standard drugs, Arch Gen Psychiatry, 59, 913, 10.1001/archpsyc.59.10.913

Petersen, 1999, Mild cognitive impairment: clinical characterization and outcome, Arch Neurol, 56, 303, 10.1001/archneur.56.3.303

Rogers, 1998, A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease, Donepezil Study Group Neurology, 50, 136

Rosen, 1984, A new rating scale for Alzheimer's disease, Am J Psychiatry, 141, 1356, 10.1176/ajp.141.11.1356

Ross, 2007, Omega-3 fatty acids as treatments for mental illness: which disorder and which fatty acid?, Lipids Health Dis, 6, 21, 10.1186/1476-511X-6-21

Ruxton, 2004, The health benefits of omega-3 polyunsaturated fatty acids: a review of the evidence, J Hum Nutr Diet, 17, 449, 10.1111/j.1365-277X.2004.00552.x

Schaefer, 2006, Plasma phosphatidylcholine docosahexaenoic acid content and risk of dementia and Alzheimer disease: the Framingham Heart Study, Arch Neurol, 63, 1545, 10.1001/archneur.63.11.1545

Schneider, 1997, Validity and reliability of the Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change. The Alzheimer's Disease Cooperative Study, Alzheimer Dis Assoc Disord, 11, S22, 10.1097/00002093-199700112-00004

Shahidi, 2004, Omega-3 (n−3) fatty acids in health and disease: Part 1—cardiovascular disease and cancer, J Med Food, 7, 387, 10.1089/jmf.2004.7.387

Solfrizzi, 1999, High monounsaturated fatty acids intake protects against age-related cognitive decline, Neurology, 52, 1563, 10.1212/WNL.52.8.1563

Song, 2004, Omega-3 fatty acid ethyl-eicosapentaenoate, but not soybean oil, attenuates memory impairment induced by central IL-1beta administration, J Lipid Res, 45, 1112, 10.1194/jlr.M300526-JLR200

Su, 2003, Omega-3 fatty acids in major depressive disorder. A preliminary double-blind, placebo-controlled trial, Eur Neuropsychopharmacol, 13, 267, 10.1016/S0924-977X(03)00032-4

Thavichachart, 2006, Efficacy study of galantamine in possible Alzheimer's disease with or without cerebrovascular disease and vascular dementia in Thai patients: a slow-titration regimen, Int J Clin Pract, 60, 533, 10.1111/j.1368-5031.2006.00892.x

Wecherler, 1997

Yehuda, 2002, The role of polyunsaturated fatty acids in restoring the aging neuronal membrane, Neurobiol Aging, 23, 843, 10.1016/S0197-4580(02)00074-X

Yehuda, 1996, Essential fatty acids preparation (SR-3) improves Alzheimer's patients quality of life, Int J Neurosci, 87, 141, 10.3109/00207459609070833